A single ICD-10 code, a missing modifier or a misclassified procedure intent can shift a colonoscopy from a fully covered preventive service to a medically necessary diagnostic one, which could change what the payer reimburses, what the patient owes and what the ASC collects.
Colonoscopy billing hinges on distinctions between screening and diagnostic intent, and that distinction is one of the most frequently mishandled in GI billing, according to a recent blog post from MBW RCM.
Here’s what ASCs need to know:
The foundational distinction
A screening colonoscopy is a preventive service performed on an asymptomatic patient. A diagnostic colonoscopy is performed when a patient has symptoms, abnormal lab results or a known GI condition requiring evaluation, according to the report. Common diagnostic indications include rectal bleeding, iron deficiency anemia, chronic diarrhea lasting more than 14 days, abdominal pain and a positive fecal immunochemical test.
The coding follows the intent. For Medicare patients, average-risk screening uses HCPCS G0121; high-risk screening uses G0105. For commercial payers, CPT 45378 with Modifier 33 appended indicates a preventive service and triggers zero patient cost-sharing under the ACA’s preventive care mandate. Without Modifier 33, the same claim processes as diagnostic, and the patient faces deductible and coinsurance.
Misclassification between screening and diagnostic colonoscopy is a leading cause of claim denial in gastroenterology, according to a 2026 billing guide from Neolytix. Misclassifying a screening colonoscopy as diagnostic, or failing to update the code when a screening converts to a diagnostic procedure, is one of the most frequent gastroenterology denial causes.
The conversion problem
The highest-risk billing moment is often the conversion, when a scheduled preventive screening finds a polyp and removes it. Screening converted to diagnostic or therapeutic is often cited as occurring in roughly 35% to 40% of preventive colonoscopies, according to the blog post. That means a significant share of every GI ASC’s colonoscopy volume involves a mid-procedure change in clinical status that must be reflected correctly in the claim.
When a screening colonoscopy becomes therapeutic, the CPT code must upgrade to reflect what was actually done, which is 45385 for snare polypectomy and 45380 for biopsy. The G-code used for the original screening intent is not carried forward. For Medicare, Modifier PT is appended to the therapeutic code. For commercial payers, Modifier 33 is used instead.
The two modifiers are not interchangeable. Using PT on a commercial claim or Modifier 33 on a Medicare claim produces automatic denials, according to a 2026 GI billing guide.
CMS has clarified multiple times that polyp removal is an integral part of screening colonoscopies and should not be considered a valid reason to reclassify the entire procedure as diagnostic. Hospitals and providers are allowed to change to a more expensive billing code if a colonoscopy is considered diagnostic rather than preventive, but the distinction is not always clear in practice.
The reimbursement difference
The work RVU values differ meaningfully across colonoscopy codes. Diagnostic colonoscopy (CPT 45378) carries 3.36 wRVUs, colonoscopy with biopsy (45380) carries 3.67 wRVUs, and colonoscopy with polypectomy (45385) carries 4.57 wRVUs. At the 2026 Medicare conversion factor of $33.42, those translate to roughly $218 to $296 in physician reimbursement before facility fees.
The facility fee differential between screening and diagnostic is equally significant. Colonoscopy screenings cost 32% more in a hospital than in an ASC, and diagnostic colonoscopies cost 58% more in a hospital outpatient department than in an ASC, according to a Blue Cross Blue Shield Association analysis.
What auditors are flagging
Auditors compare clinical notes against billed codes. If a physician documents “screening colonoscopy with polypectomy” but the claim line shows only G0121, the mismatch suggests underreporting or improper billing. Each claim line and modifier must reflect what the physician documented, according to billing guidance cited in PROMBS’ analysis of CMS requirements.
The ACA coinsurance issue has drawn specific enforcement attention. Hospitals and providers that reclassify screening colonoscopies as diagnostic after polyp removal, shifting cost-sharing responsibility to patients who believed their procedure was fully covered, have faced scrutiny under the ACA’s preventive care mandate.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.